Drug Trial Radar · NCT05323981
Comparison of Pharmacokinetics and Safety of HS627(2 Specifications) Versus PERJETA With a Single Injection
Last checked: Nov 19, 2026Latest source record: Jul 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
180
Actual
Start
Apr 11, 2022
Primary completion
Oct 9, 2022
Study completion Oct 9, 2022
Sponsor
- Lead sponsor
- BioRay Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 12, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the bioequivalence of HS627(2 specifications) with PERJETA in a single intravenous administration in healthy subjects
Conditions
- Similarity of Pharmacokinetics and Safety
Interventions
HS627(210mg/7ml)Drug
Intravenous drip of 420mg HS627
HS627(420mg/14ml)Drug
Intravenous drip of 420mg HS627
PerjetaDrug
Intravenous drip of 420mg PERJETA
Primary outcomes
What the sponsor says the trial is designed to measure.
- (AUC0-∞)of HS627(2 specifications) and PERJETATime frame: 85Days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.